- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05536752
Estudio de fase II QA102 en sujetos con AMD seca (AMEND)
Un estudio de fase 2, doble ciego, aleatorizado, controlado con placebo, de respuesta a la dosis que evalúa la seguridad y la eficacia de QA102 en sujetos con degeneración macular seca relacionada con la edad (AMD)
This is a phase 2, double-masked, randomized, placebo-controlled, dose-response study. The primary objective of the study is to evaluate the efficacy of QA102 oral capsules on the development of soft drusen, visual acuity (VA), and geographic atrophy (GA) or choroidal neovascularization (CNV) or the progression of GA in subjects with intermediate to advanced dry AMD.
Descripción general del estudio
Estado
Intervención / Tratamiento
Descripción detallada
Approximately 30 sites will randomize a total of approximately 150 subjects to 1 of 3 treatment arms in a 1:1:1 ratio (50 subjects per arm). Each subject will receive either QA102 or matching placebo BID for up to 15 months.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Arizona
-
Phoenix, Arizona, Estados Unidos, 85021
- Associated Retina Consultants
-
-
California
-
Mountain View, California, Estados Unidos, 94040
- Northern California Retina Vitreous Associates Medical Group
-
Pasadena, California, Estados Unidos, 91107
- California Eye Specialists Medical Group
-
Redlands, California, Estados Unidos, 91107
- California Eye Specialists Medical Group
-
-
Colorado
-
Colorado Springs, Colorado, Estados Unidos, 80909
- Retina Consultants of Southern Colorado, P.C.
-
-
Florida
-
Deerfield Beach, Florida, Estados Unidos, 33064
- Advanced Research
-
Fort Myers, Florida, Estados Unidos, 33912
- National Ophthalmic Research Institute
-
Miami, Florida, Estados Unidos, 33143
- MedEye Associates
-
Pensacola, Florida, Estados Unidos, 32503
- Retina Specialty Institute
-
Pinellas Park, Florida, Estados Unidos, 33782
- Eye Associates of Pinellas
-
Sarasota, Florida, Estados Unidos, 34239
- Sarasota Retina Institute
-
Winter Haven, Florida, Estados Unidos, 33880
- Vitreous and Retina Consultants
-
-
Georgia
-
Marietta, Georgia, Estados Unidos, 30060
- Marietta Eye Clinic
-
-
Illinois
-
Oak Forest, Illinois, Estados Unidos, 60452
- University Retina and Macula Associates
-
-
Louisiana
-
West Monroe, Louisiana, Estados Unidos, 71291
- Northeast Louisiana dba Haik Humble Eye Center
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21209
- The Retina Care Center
-
Hagerstown, Maryland, Estados Unidos, 21740
- Cumberland Valley Retina Consultants
-
Hagerstown, Maryland, Estados Unidos, 21740
- Mid Atlantic Retina Specialists
-
-
Massachusetts
-
Worcester, Massachusetts, Estados Unidos, 01605
- Vitreo-Retinal Associates, P.C.
-
-
Missouri
-
St Louis, Missouri, Estados Unidos, 63144
- Retina Research Institute
-
-
Ohio
-
Cincinnati, Ohio, Estados Unidos, 45202
- Velocity Clinical Research
-
-
Oregon
-
Eugene, Oregon, Estados Unidos, 97401
- Verum Research, LLC
-
-
Pennsylvania
-
Erie, Pennsylvania, Estados Unidos, 16507
- Erie Retina Research
-
-
Texas
-
Abilene, Texas, Estados Unidos, 79606
- Retina Research Institute of Texas
-
Austin, Texas, Estados Unidos, 78705
- Austin Research Center for Retina
-
Dallas, Texas, Estados Unidos, 75243
- AXIS Clinicals LLC / Retina of North Texas
-
Plano, Texas, Estados Unidos, 75075
- Texas Retina Associates - Plano
-
San Antonio, Texas, Estados Unidos, 78215
- San Antonio Eye Center
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84107
- Rocky Mountain Retina Consultants
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Key Inclusion Criteria:
- Subject must be able to understand and willing to sign a written informed consent form (ICF) prior to the initiation of any study-specific procedures.
- Subject must be age ≥50 years at the time of informed consent.
- Subject must be able to take oral medications and willing to record daily adherence to taking their assigned capsules.
- Subject must have adequate hematologic function, hepatic function, renal function and coagulation profile as defined in the protocol.
- Subject must be willing and able to comply with study procedures and examinations.
Specific to the Study Eye:
-
Subject must have one of the following:
- extensive intermediate-size drusen, or at least 1 large drusen, or
- GA ((not involving the foveal center point) secondary to AMD, with very limited aggregate size of total GA(s), as defined in the protocol.
-
Subject must be able to correctly identify ≥35 ETDRS letters (approximately 20/200 Snellen equivalent).
Specific to Fellow Eye:
- Subject must have a diagnosis of advanced AMD (evidence of GA and/or CNV), to be confirmed by the CRC.
Specific to Both Eyes:
- Subject must have visualizable retina, clear ocular media, and adequate pupillary dilation to ensure high-quality fundus imaging.
Key Exclusion Criteria:
- Subject received an active investigational drug within 6 weeks (or 5 half-lives of the active, whichever is longer) prior to screening for this QA102 study.
- Subject has ever received gene therapy (for any condition).
- Subject is unwilling to stop intake of Age-Related Eye Disease Studies (AREDS) vitamins for the duration of the study.
- Subject has a clinically significant systemic disease that might interfere with the study, in the judgment of the Investigator.
- Subject had major surgery within 30 days prior to Screening.
Specific to Study Eye:
- Subject has large GA, subfoveal GA, or active or inactive CNV, as confirmed by the CRC.
- Subject has GA or CNV due to causes other than AMD that that developed between Visit 1 (Screening) and Visit 2 (Randomization).
- Subject has endophthalmitis.
- Subject has a hemorrhagic or serous pigment epithelial detachment (PED) within 500 µm of the foveal center point, to be confirmed by the CRC.
- Subject has had retinal procedures or surgeries, or has a retinal pathology, such as a macular hole.
- Subject has aphakia or absence of the posterior capsule.
- Subject has ever received, whether in an interventional trial or by prescription, an FDA- approved treatment for GA. Use of such treatment during the QA102 study period also is prohibited. (Study Eye Only)
Specific to Fellow Eye:
Subject has monocular vision impairment, defined as having no light perception in the fellow eye with adequate vision in the study eye.
Specific to Either Eye:
- Subject had intraocular surgery with lens replacement within 3 months of Screening.
- Subject has any ophthalmic condition that could require surgery during the study period.
- Subject has an ocular condition that might affect adequate imaging of the retina and/or or alter visual acuity.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Triple
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: QA102 200mg group
Subjects randomized to this arm will receive one (1) 200 mg capsule of QA102 and 1 placebo capsule BID = daily dose of 400 mg QA102 for up to 15 months |
Capsules |
|
Experimental: QA102 400mg group
Subjects randomized to this arm will receive two (2) 200 mg capsules of QA102 BID = daily dose of 800 mg QA102 for up to 15 months |
Capsules |
|
Comparador de placebos: Placebo group
Subjects randomized to this arm will receive two (2) placebo capsules BID = daily dose of 0 mg QA102 for up to 15 months |
Capsules |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change From Baseline in Soft Drusen Volume (mm3)
Periodo de tiempo: Month 12
|
Change from baseline in soft drusen volume (mm3), Efficacy-Evaluable Analysis Set |
Month 12
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Mean Rate of GA Growth
Periodo de tiempo: Month 12
|
Mean Rate of Growth in GA (mm2) (Square Root Transformation) from Baseline |
Month 12
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Otros números de identificación del estudio
- QA102-CS201
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .